| 000 | 01119 a2200301 4500 | ||
|---|---|---|---|
| 005 | 20250515060837.0 | ||
| 264 | 0 | _c20070511 | |
| 008 | 200705s 0 0 eng d | ||
| 022 | _a0889-8529 | ||
| 024 | 7 |
_a10.1016/j.ecl.2006.11.007 _2doi |
|
| 040 |
_aNLM _beng _cNLM |
||
| 100 | 1 | _aBanerjee, Indraneel | |
| 245 | 0 | 0 |
_aGrowth hormone treatment and cancer risk. _h[electronic resource] |
| 260 |
_bEndocrinology and metabolism clinics of North America _cMar 2007 |
||
| 300 |
_a247-63 p. _bdigital |
||
| 500 | _aPublication Type: Journal Article; Review | ||
| 650 | 0 | 4 | _aDisease Progression |
| 650 | 0 | 4 |
_aGrowth Disorders _xcomplications |
| 650 | 0 | 4 |
_aGrowth Hormone _xadverse effects |
| 650 | 0 | 4 | _aHumans |
| 650 | 0 | 4 |
_aNeoplasm Recurrence, Local _xchemically induced |
| 650 | 0 | 4 |
_aNeoplasms _xchemically induced |
| 650 | 0 | 4 | _aRisk Factors |
| 650 | 0 | 4 |
_aSomatomedins _xphysiology |
| 700 | 1 | _aClayton, Peter E | |
| 773 | 0 |
_tEndocrinology and metabolism clinics of North America _gvol. 36 _gno. 1 _gp. 247-63 |
|
| 856 | 4 | 0 |
_uhttps://doi.org/10.1016/j.ecl.2006.11.007 _zAvailable from publisher's website |
| 999 |
_c16893810 _d16893810 |
||